Department of Neonatology, University of Health Sciences, Dr. Sami Ulus Maternity and Children Research and Training Hospital, Ankara, Turkey
Department of Pediatrics, Division of Neonatology, Faculty of Medicine, Ankara University, Ankara, Turkey
Turk J Med Sci. 2020 Feb 13;50(1):12-17. doi: 10.3906/sag-1811-8.
BACKGROUND/AIM: Most inborn metabolic diseases are diagnosed during the neonatal period. The accumulation of toxic metabolites may cause acute metabolic crisis with long-term neurological dysfunction and death. Renal replacement therapy (RRT) modalities allow the efficient removal of toxic metabolites. In this study, we reviewed our experience with continuous venovenous hemodiafiltration (CVVHDF) as RRT for newborns with an inborn metabolic disease.
Patients diagnosed with an inborn metabolic disease and who received CVVHDF treatment at our neonatal intensive care unit between January 2014 and December 2017 were included in this study. Their demographic and clinical data were collected, and the efficacy and safety of CVVHDF was evaluated.
A total of nine continuous RRT (CRRT) sessions as CVVHDF were performed in eight newborns with a diagnosis of urea cycle defect (n = 5), maple syrup urine disease (n = 2), or methylmalonic acidemia (n = 1). The mean age at admission was 10 ± 8.6 days (range: 3–28 days). The mean plasma levels of ammonium were 1120 ± 512.6 mg/dL and 227.5 ± 141.6 mg/dL before and at the end of the treatment, respectively. Plasma levels of leucine were 2053.5 ± 1282 μmol/L and 473.5 ± 7.8 μmol/L before and at the end of the treatment, respectively. The CVVHDF duration was 32.3 ± 11.1 h (median: 37 h; range: 16–44 h), and the mean length of hospitalization was 14.6 ± 12.9 days. The mean duration of CVVHDF was 32.3 ± 11.1 h (range: 16–44 h). Circuit clotting was the most common observed complication (37.5%) and the survival rate was 50%. Among surviving patients, two developed severe and two developed mild mental and motor retardation.
CVVHDF is a CRRT modality that can be used to treat newborns with an inborn metabolic disease. Early diagnosis, commencement of specific medical therapy, diet, and extracorporeal support, if needed, are likely to result in improved short and long- term outcomes.
背景/目的:大多数先天性代谢疾病在新生儿期被诊断出来。有毒代谢物的积累可能导致急性代谢危机,并伴有长期神经功能障碍和死亡。肾脏替代疗法(RRT)模式可有效清除有毒代谢物。在本研究中,我们回顾了我们使用连续静脉-静脉血液透析滤过(CVVHDF)作为新生儿先天性代谢疾病的 RRT 的经验。
本研究纳入了 2014 年 1 月至 2017 年 12 月在我们新生儿重症监护病房接受 CVVHDF 治疗的先天性代谢疾病患者。收集了他们的人口统计学和临床数据,并评估了 CVVHDF 的疗效和安全性。
8 例新生儿共进行了 9 次连续肾脏替代治疗(CRRT)作为 CVVHDF,其中尿素循环缺陷(n=5)、枫糖尿症(n=2)或甲基丙二酸血症(n=1)各 1 例。入院时的平均年龄为 10±8.6 天(范围:3-28 天)。治疗前和治疗结束时的平均血氨水平分别为 1120±512.6mg/dL 和 227.5±141.6mg/dL。治疗前和治疗结束时的亮氨酸水平分别为 2053.5±1282μmol/L 和 473.5±7.8μmol/L。CVVHDF 持续时间为 32.3±11.1h(中位数:37h;范围:16-44h),平均住院时间为 14.6±12.9 天。CVVHDF 的平均持续时间为 32.3±11.1h(范围:16-44h)。回路凝血是最常见的观察到的并发症(37.5%),存活率为 50%。在存活的患者中,有 2 例出现严重智力和运动发育迟缓,有 2 例出现轻度智力和运动发育迟缓。
CVVHDF 是一种 CRRT 模式,可用于治疗新生儿先天性代谢疾病。早期诊断、开始特定的医学治疗、饮食以及如果需要的体外支持,可能会改善短期和长期预后。